Pfizer Inc.’s Fablyn, the bone drug that failed to win U.S. approval amid safety questions, reduced the risk of breast cancer and fractures in postmenopausal women with osteoporosis, a company-sponsored study found.
Women taking the medicine, also known as lasofoxifene, had a 79 percent lower chance of breast cancer compared with those on placebo, researchers said today in the Journal of the National Cancer Institute. Pfizer is “exploring strategic options” that include licensing out Fablyn or selling the rights Pfizer now holds, in line with plans disclosed last year, Victoria Davis, a spokeswoman, said in an e-mail yesterday.
